SSKN director Form 4 shows November 2025 insider trades

STRATA Skin Sciences (SSKN) reported insider trading activity by a director.

Rhea-AI Filing Summary

STRATA Skin Sciences (SSKN) reported insider trading activity by a director. On 11/17/2025, the director sold three blocks of common stock: 5,500 shares at $1.32, 7,200 shares at $1.34, and 1,394 shares at $1.36. On 11/18/2025, the same person purchased 2,168 shares at $1.40 and 2,832 shares at $1.41. After these transactions, the director held 8,766 shares of STRATA Skin Sciences common stock with direct ownership.

Insider Trade Summary

Net Seller: 9,094 shares

Net Sell 5 txns

Insider Rubinstein Samuel

Role Director

Bought 5,000 shs ($7K)

Sold 14,094 shs ($19K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	2,168	$1.40	$3K
Purchase	Common Stock	2,832	$1.41	$4K
Sale	Common Stock	5,500	$1.32	$7K
Sale	Common Stock	7,200	$1.34	$10K
Sale	Common Stock	1,394	$1.36	$2K

Holdings After Transaction: Common Stock — 8,766 shares (Direct)

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What type of SEC filing did STRATA Skin Sciences (SSKN) submit?

STRATA Skin Sciences filed a Form 4, which reports changes in the beneficial ownership of the company’s equity securities by an insider.

Who reported trades in STRATA Skin Sciences (SSKN) stock on this Form 4?

A company director reported the trades, as indicated by the checked relationship box for director on the form.

What STRATA Skin Sciences (SSKN) stock sales were reported on 11/17/2025?

On 11/17/2025, the director sold 5,500 shares at $1.32, 7,200 shares at $1.34, and 1,394 shares at $1.36 per share.

What STRATA Skin Sciences (SSKN) stock purchases were reported on 11/18/2025?

On 11/18/2025, the director purchased 2,168 shares at $1.40 and 2,832 shares at $1.41 per share.

How many STRATA Skin Sciences (SSKN) shares does the director own after the reported trades?

Following the reported transactions, the director beneficially owned 8,766 shares of STRATA Skin Sciences common stock with direct ownership.

Does the Form 4 indicate whether the filing is for one or multiple reporting persons for STRATA Skin Sciences (SSKN)?

The filing indicates that it is a Form filed by One Reporting Person, not a joint filing by multiple insiders.

Were any derivative securities reported for STRATA Skin Sciences (SSKN) on this Form 4?

The section for derivative securities is present but does not list any specific derivative transactions in the provided content.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/18/2025 - 04:35 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rubinstein Samuel

(Last) (First) (Middle)

STRATA SKIN SCIENCES, INC.

5 WALNUT GROVE DRIVE, SUITE 140

(Street)

HORSHAM PA 19044

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
STRATA Skin Sciences, Inc. [ SSKN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/17/2025		S		5,500	D	$1.32	12,360	D
Common Stock	11/17/2025		S		7,200	D	$1.34	5,160	D
Common Stock	11/17/2025		S		1,394	D	$1.36	3,766	D
Common Stock	11/18/2025		P		2,168	A	$1.4	5,934	D
Common Stock	11/18/2025		P		2,832	A	$1.41	8,766	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Samuel Rubinstein	11/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.